Parexel said today that it would go private after Pamplona Capital agreed to buy the pharmaceutical research services company in a deal valued at $5 billion. Pamplona is slated to pay $88.10 per share for Parexel, which is a 5% premium to the stock’s close on Monday. Get the full story at our sister site, […]
Parexel International
Sanofi, Parexel collaborate on clinical trial data collection wearables
Parexel said today it is collaborating with Sanofi (NYSE:SNY) to develop and promote wearable devices to improve collection of data during clinical trials. Through the collaborative deal, the 2 companies will leverage their specific expertise to explore how wearables could improve study performance and new drug development and how sensors from several wearable devices could be […]
Parexel shares slide on embezzlement news
Parexel saw shares drop 4.3% after releasing information on the embezzlement of corporate funds at one of the company’s international operations in an SEC filing. Get the full story at our sister site, Medical Design & Outsourcing.
Parexel picks up life sciences strat firm Health Advances
Parexel International said yesterday it bought life sciences strategy consulting firm Health Advances through the acquisition of all outstanding equity securities of the company. Health Advances employs 120 scientists, clinicians and business professionals across the U.S. and Europe, Parexel International said. The firm works with leading medical device, diagnostic and health information companies, providing specialized […]
ConforMIS lands $1.4 million MassDevelopment loan | Funding Roundup
ConforMIS Inc. is on a roll the announcement that it secured a $1.4 million loan from MassDevelopment’s Emerging Technology Fund.
The loan will go toward growing the Burlington, Mass.-based company’s supply chain and manufacturing capacity for its iTotal customized knee replacement system.
300 jobs, 28% of beds cut in Parexel early stage restructuring
Parexel International Corp. (NSDQ:PRXL) will close four of its international early-phase facilities and downsize the other five, cutting 300 jobs in the process.
Despite an 23 percent increase in profits in the three months ending March 31 as compared with the same time last year, the prominent CRO reported in May that early phase work continued to show revenue shortfalls.
Haemonetics breaks annual sales record, Q4 profits up five fold | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Earnings roundup: Vascular Solutions profits rocket 838 percent
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Parexel opens another office in Japan
Parexel International Corp. (NSDQ:PRXL) brought the number of its offices in Japan to three with the addition of a new office in Nagoya.
The Waltham, Mass.-based clinical research organization established the new location to prop up its clinical development and regulatory consulting operations both in the Land of the Rising Sun and the Asia-Pacific region.
Parexel International ends fiscal 2010 in the black
Parexel International Corp. (NSDQ:PRXL) wrapped up its fiscal 2010 reporting a 19.4 percent increase in overall sales and adjusted net earnings of $19.1 million.
The 32-cent per share adjusted profit — which excludes just under $10 million for restructuring costs and other special charges during the three months ended June 30 — topped both Wall Street expectations and year-ago comparisons. The Waltham, Mass.-based clinical research organization also boosted its revenue guidance for the upcoming fiscal year by $20 million, up to a new range of between $1.27 billion to $1.31 billion.
Parexel taps former regulatory officials for consulting group
Waltham-based contract research organization Parexel International Corp. (NSDQ:PRXL) hired two former regulatory scientists for its Parexel Consulting division.
The company added Dr. Toby Silverman, who oversaw aspects of the Food & Drug Administration’s Center for Biologics Evaluation and Research, and Keith Watson, a former employee of the U.K.’s Medicines and Healthcare products Regulatory Agency, where he was a liaison to several European biotechnology safety organizations.*
